JP2022502015A5 - - Google Patents

Info

Publication number
JP2022502015A5
JP2022502015A5 JP2021514551A JP2021514551A JP2022502015A5 JP 2022502015 A5 JP2022502015 A5 JP 2022502015A5 JP 2021514551 A JP2021514551 A JP 2021514551A JP 2021514551 A JP2021514551 A JP 2021514551A JP 2022502015 A5 JP2022502015 A5 JP 2022502015A5
Authority
JP
Japan
Prior art keywords
peptide
cancer
seq
fragment
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021514551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502015A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/074898 external-priority patent/WO2020058285A1/en
Publication of JP2022502015A publication Critical patent/JP2022502015A/ja
Publication of JP2022502015A5 publication Critical patent/JP2022502015A5/ja
Ceased legal-status Critical Current

Links

JP2021514551A 2018-09-17 2019-09-17 がんに対する免疫療法で使用するためのb*44拘束性ペプチドおよび関連方法 Ceased JP2022502015A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862732300P 2018-09-17 2018-09-17
DE102018122623 2018-09-17
US62/732,300 2018-09-17
DE102018122623.3 2018-09-17
PCT/EP2019/074898 WO2020058285A1 (en) 2018-09-17 2019-09-17 B*44 restricted peptides for use in immunotherapy against cancers and related methods

Publications (2)

Publication Number Publication Date
JP2022502015A JP2022502015A (ja) 2022-01-11
JP2022502015A5 true JP2022502015A5 (https=) 2022-09-29

Family

ID=67999633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514551A Ceased JP2022502015A (ja) 2018-09-17 2019-09-17 がんに対する免疫療法で使用するためのb*44拘束性ペプチドおよび関連方法

Country Status (19)

Country Link
US (18) US11945850B2 (https=)
EP (1) EP3853243A1 (https=)
JP (1) JP2022502015A (https=)
KR (1) KR20210061340A (https=)
CN (1) CN112789285A (https=)
AU (1) AU2019344565B2 (https=)
BR (1) BR112021004170A2 (https=)
CA (1) CA3108578A1 (https=)
CL (1) CL2021000649A1 (https=)
CO (1) CO2021004270A2 (https=)
CR (1) CR20210140A (https=)
IL (2) IL309716A (https=)
MA (1) MA53641A (https=)
MX (1) MX2021003067A (https=)
PE (1) PE20211642A1 (https=)
PH (1) PH12021550346A1 (https=)
SG (1) SG11202101924QA (https=)
TW (1) TW202028224A (https=)
WO (1) WO2020058285A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
US10738100B2 (en) * 2017-01-27 2020-08-11 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SI3573647T1 (sl) 2017-01-27 2023-07-31 Immatics Biotechnologies Gmbh Peptidi in kombinacija peptidov za uporabo v imunoterapiji proti raku jajčnikov in drugim oblikam raka
MX2019015879A (es) 2017-07-07 2020-02-07 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinacones de peptidos para el uso en la inmunoterapia contra el cancer de pulmon, incluyendo el nsclc, el sclc y otros canceres.
US10800823B2 (en) 2017-07-07 2020-10-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
TW202028224A (zh) 2018-09-17 2020-08-01 德商英麥提克生物技術股份有限公司 B*44限制肽在抗癌免疫治療的用途和相關方法
EP4091627A1 (en) * 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
WO2024178334A1 (en) * 2023-02-24 2024-08-29 The Children's Hospital Of Philadelphia Improved phox2b pc-car generation based on structure and saturation mutagenesis

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
LU88258I2 (https=) 1978-12-22 1994-02-03
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5977300A (en) 1994-06-03 1999-11-02 Ludwig Institute Of Cancer Research Isolated nonapeptide which bind to HLA-B44 molecules and the uses thereof
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO2001053833A1 (en) 2000-01-20 2001-07-26 Ludwig Institute For Cancer Research Mage antigenic peptides which bind hla-b35 and hla-b44
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
AU7524601A (en) 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
US20030171275A1 (en) 2000-12-20 2003-09-11 Baughn Mariah R. Transporters and ion channels
US20030087245A1 (en) 2001-01-24 2003-05-08 Eos Biotechnology, Inc. Uses of PBH1 in the diagnosis and therapeutic treatment of prostate cancer
WO2003004989A2 (en) 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
US7311914B2 (en) 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
PT1558643E (pt) 2002-11-09 2009-08-24 Immunocore Ltd Apresentação de um receptor das células t
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US7348007B2 (en) 2004-02-09 2008-03-25 Ludwig Institute For Cancer Research Mage C2 antigenic peptides and uses thereof
US7883858B2 (en) 2005-01-27 2011-02-08 Institute For Systems Biology Methods for identifying and monitoring drug side effects
SI1806358T1 (sl) 2005-09-05 2010-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II
WO2007053570A2 (en) 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. A polypeptide complex of trpm8 and calmodulin and its uses thereof
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
EP2632955A1 (en) 2010-10-26 2013-09-04 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
EP2663672A1 (en) 2011-01-11 2013-11-20 University Health Network Prognostic signature for oral squamous cell carcinoma
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
ES2603589T3 (es) 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
CN114085283A (zh) 2015-05-19 2022-02-25 拉·约拉过敏反应及免疫医学研究所 调节炎症应答及治疗不良心血管事件、病和粥样硬化的人apob100表位、方法和用途
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201520541D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
HUE067838T2 (hu) * 2016-09-21 2024-11-28 Amal Therapeutics Sa Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére
CN110651189B (zh) * 2017-03-03 2024-10-25 特雷斯生物有限公司 肽疫苗
WO2018189148A1 (en) 2017-04-10 2018-10-18 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
EA201992416A1 (ru) 2017-04-10 2020-02-25 Имматикс Байотекнолоджиз Гмбх Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
US10800823B2 (en) 2017-07-07 2020-10-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
TW202028224A (zh) * 2018-09-17 2020-08-01 德商英麥提克生物技術股份有限公司 B*44限制肽在抗癌免疫治療的用途和相關方法

Similar Documents

Publication Publication Date Title
JP2024041841A5 (https=)
JP2022502015A5 (https=)
JP2024099580A5 (https=)
JP2021535900A5 (https=)
JP2019511214A5 (https=)
JP2022502358A5 (https=)
JP2021514178A5 (https=)
JP2021168652A5 (https=)
JP6639233B2 (ja) Mage−a1を認識する高結合活性結合分子
JP2019502360A5 (https=)
JP2021528046A5 (https=)
JP2020516681A5 (https=)
JP2019516663A5 (https=)
JP2019510465A5 (https=)
JP2020191862A5 (https=)
JP2019506838A5 (https=)
RU2017137142A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
JP2018510628A5 (https=)
JP2018536383A5 (https=)
JP2018520653A5 (https=)
JP2018529320A5 (https=)
JP2018518937A5 (https=)
JP2018509135A5 (https=)
JP2018519243A5 (https=)
JP2018511321A5 (https=)